ストックスクリーナーアプリを入手
15.55
0.45%
0.07
プレマーケット:
15.55
前日終値:
$15.48
開ける：
$15.25
24時間の取引高:
823.62K
Relative Volume:
0.70
時価総額：
$853.18M
収益：
$15.84M
当期純損益:
$-308.48M
株価収益率:
-2.3997
EPS:
-6.48
ネットキャッシュフロー:
$-153.08M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
+7.24%
6か月 パフォーマンス:
+21.11%
1年 パフォーマンス:
+121.19%
1日の値動き範囲:
$15.17
$15.66
1週間の範囲:
$14.70
$16.66
52週間の値動き範囲:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
QURE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.55 | 859.22M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure N V (QURE) 最新ニュース
uniQure N.V. Facing Inflection Point in Trend AnalysisJuly 2025 Trends & AI Enhanced Execution Alerts - beatles.ru
Short Term Trend Reversal in uniQure N.V. PossibleJuly 2025 Fed Impact & Free High Accuracy Swing Entry Alerts - 선데이타임즈
What to expect from uniQure N.V. in the next 30 daysTrade Volume Report & Consistent Return Strategy Ideas - Newser
Visual analytics tools that track uniQure N.V. performanceJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Smart tools for monitoring uniQure N.V.’s price actionWeekly Trade Review & Free Technical Confirmation Trade Alerts - Newser
Using fundamentals and technicals on uniQure N.V.Market Activity Recap & Entry Point Confirmation Signals - Newser
How to use Fibonacci retracement on uniQure N.V.Quarterly Portfolio Report & Long-Term Growth Portfolio Plans - Newser
uniQure N.V’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Momentum divergence signals in uniQure N.V. chart2025 Market Trends & Fast Entry High Yield Stock Tips - Newser
How uniQure N.V. stock performs during market volatilityBull Run & Real-Time Chart Breakout Alerts - Newser
Biotech And Pharma Stocks Rally After Positive News And Upgrades - Finimize
UniQure Shares Rise After Mizuho Upgrade - MarketScreener
Mizuho Securities Upgrades UniQure NV(QURE.US) to Buy Rating, Announces Target Price $30 - 富途牛牛
uniQure stock rating upgraded by Mizuho on Huntington’s disease therapy potential - Investing.com
How sentiment analysis helps forecast uniQure N.V.ROI Focused Setup Screener With Exit Markers - Newser
uniQure N.V. stock trend outlook and recovery pathPortfolio Review Summary with Five-Year Outlook - Newser
Will uniQure N.V. price bounce be sustainableWeekly Breakout Forecast with Entry Zones - Newser
Institutional Ownership Dominates uniQure N.V., Hedge Funds Hold 19% - AInvest
uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - uk.finance.yahoo.com
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
Aberdeen Group Expands Stake in uniQure with Strategic Acquisition - AInvest
Aberdeen Group plc Expands Stake in uniQure NV with Strategic Ac - GuruFocus
How high can uniQure N.V. stock price go in 2025AI Powered Buy Point Forecast Planner - Newser
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Wall Street Zen - Defense World
Is uniQure N.V. a good long term investmentGet exclusive access to premium stock research - Jammu Links News
What is uniQure N.V. company’s growth strategyStrongest growth potential - Jammu Links News
Should I hold or sell uniQure N.V. stock in 2025Unlock daily market insights for better trades - Jammu Links News
What makes uniQure N.V. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What drives uniQure N.V. stock priceUnprecedented market success - Jammu Links News
Is uniQure N.V. a growth stock or a value stockMaximize returns with disciplined investment techniques - Jammu Links News
What is the risk reward ratio of investing in uniQure N.V. stockOutstanding growth strategies - Jammu Links News
What are the latest earnings results for uniQure N.V.Discover undervalued stocks before they soar - Jammu Links News
How does uniQure N.V. compare to its industry peersMaximize your gains with expert trading tips - Jammu Links News
Is uniQure N.V. stock overvalued or undervaluedDiscover high-impact stocks for your portfolio - Jammu Links News
What analysts say about uniQure N.V. stockDiscover breakthrough stocks before the crowd - Jammu Links News
How strong is uniQure N.V. company’s balance sheetBuild wealth faster with professional insights - Jammu Links News
What are the technical indicators suggesting about uniQure N.V.High-octane gains - Jammu Links News
What is HC Wainwright’s Forecast for uniQure Q3 Earnings? - Defense World
Why is uniQure N.V. stock attracting strong analyst attentionEntry Signal Signals To Watch Now - Jammu Links News
UniQure N.V. (NASDAQ:QURE) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛
uniQure Reports Q2 2025 Progress and Financials - TipRanks
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Zacks Investment Research
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey
Uniqure N V (QURE) 財務データ
収益
当期純利益
現金流量
EPS
Uniqure N V (QURE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
| POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
| Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
| Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
| Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
| Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
| Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
| Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
| Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
1.55%
0.38%
大文字化:
|
ボリューム (24 時間):